PharmaCorp Rx — Capital/Financing Update 2025

Nov 8, 2025

MINTZ

200 Bay Street, South Tower
Suite 2800
Toronto, ON
647 499 2828
mintz.com

November 7, 2025

VIA SEDAR+

Financial and Consumer Affairs Authority of Saskatchewan, as principal regulator
Ontario Securities Commission
British Columbia Securities Commission
Alberta Securities Commission
Manitoba Securities Commission
Financial and Consumer Services Commission - New Brunswick
Nova Scotia Securities Commission
Financial and Consumer Services Division - Prince Edward Island
Office of the Superintendent of Securities Services - Newfoundland and Labrador

Dear Sirs/Mesdames:

Re: PharmaCorp Rx Inc. - Prospectus Supplement dated November 7, 2025 to the Short Form Base Shelf Prospectus dated October 14, 2025 (the "Prospectus Supplement")

We hereby consent to the reference to our name on the face page and under the heading "Legal Matters" in the Prospectus Supplement relating to the offering of units of PharmaCorp Rx Inc.

We have read the Prospectus Supplement and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus Supplement that are within our knowledge as a result of services we performed in connection with the Prospectus Supplement.

Yours truly,

(signed) "Mintz LLP"

BOSTON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO TORONTO WASHINGTON
MINTZ LLP